drugset
drugset / Trial / NCT05171855

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

NCT05171855 ↗

Phase 3 Completed 220 enrolled Ascendis Pharma Endocrinology Division A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).

Timeline

Start
2021-12-16
Primary completion
2024-12-23
Completion
2024-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Lonapegsomatropin Protein / enzyme biologic — Subcutaneous

Indications

pituitary deficiency